[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"King Chulalongkorn Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,69,92,118,147,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613026","the-difference-in-carbon-footprint-between-diagnostic-upper-gi-endoscopy-in-dyspeptic-patients-versus-therapeutic-upper-gi-bleeding-100613026",false,"NCT07261228","The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper GI Bleeding","THE DIFFERENCE IN CARBON FOOTPRINT BETWEEN DIAGNOSTIC UPPER GI ENDOSCOPY IN DYSPEPTIC PATIENTS VERSUS THERAPEUTIC UPPER GI BLEEDING","Inclusion Criteria:\n\n* Patients with dyspepsia or non-variceal upper GI bleeding\n* Age 20-80 years\n* Body mass index of 30 or less;\n* Receiving one of the following procedure during upper GI endoscopy:\n\nFor diagnostic endoscopy: Rapid urease test for H. pylori infection For therapeutic endoscopy: stop bleeding with either Argon plasma coagulation or Bipolar hemostasis probe or Hemostasis clip\n\nExclusion Criteria:\n\n* Platelet \\\u003C 50,000\n* INR \\> 2.5\n* Pregnancy\n* History of allergy to IV sedative medication\n* Peptic ulcer grade IIc and III according to Forrest classification\n* Patient receiving inhalation anesthesia","ALL","20 Years","80 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the carbon footprint produced from diagnostic upper GI endoscopy in patients with dyspepsia and therapeutic upper GI endoscopy in patients with non-variceal upper GI bleeding. The main question it aims to answer is:\n\n• How much carbon footprint is generated from upper GI endoscopy Participants are already receiving diagnostic and therapeutic upper GI endoscopy as part of their regular medical care for dyspepsia and non-variceal upper GI bleeding, respectively. The carbon footprint generated from this treatment process is examined.",[25,26,27],"Carbon Footprint in Upper GI Endoscopy","Dyspepsia","Non-variceal Upper Gastrointestinal Bleeding",[29,30,31,26,32],"Carbon footprint","Upper GI endoscopy","EGD","Non-variceal upper gastrointestinal bleeding","RECRUITING","2025-11-21",{"date":36,"type":37},"2025-12-03","ACTUAL",{"date":39,"type":37},"2025-06-01",{"date":41,"type":21},"2025-12-31",{"name":43,"class":44},"King Chulalongkorn Memorial Hospital","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100606153","the-carbon-footprint-study-of-colonoscopy-100606153","NCT07171853","The Carbon Footprint Study of Colonoscopy","The Carbon Footprint Study of Colonoscopy for Colorectal Cancer Screening and Various Techniques of Colonic Polypectomy","Inclusion Criteria:\n\n* Patients aged 18-80 years\n\nExclusion Criteria:\n\n* Patient status grade III-V according to the American Society of Anesthesiologists (ASA)\n* Poor bowel preparation (grade \\\u003C6 in the Boston Bowel Preparation Scale \\[BBPS\\])\n* Endoscopic JNET type III or suspicion of malignancy\n* Hematologic or coagulation disorders, Plt\\\u003C140,000\u002FmcL, INR\\>1.5\n* anti-platelet\u002Fanticoagulant medication that could not be paused as recommended in the current guideline\n* Emergency colonoscopy, GI bleeding, unstable vital sign, critical ill patient\n* Inflammatory bowel disease\n* Pregnancy\n* Severe cardiopulmonary disease\n* Severe infection\n* Malignancy\n* History of allergy to IV sedative medication","18 Years",{"count":55,"type":21},150,"With global warming intensifying, GI endoscopy is among the top three greenhouse gas-emitting medical procedures. Colonoscopy, a cornerstone for colorectal cancer (CRC) screening, significantly contributes to the carbon footprint (CF). This study quantifies CO₂ emissions in different steps of colonoscopy and evaluates the environmental impact of common polypectomy techniques to establish baseline CF data and identify opportunities for mitigation. This study included patients undergoing colonoscopy for CRC screening. CO₂ emissions were comprehensively measured at each step of the procedure (pre-, during, and post-colonoscopy), including energy consumption, all equipment and medications, waste management, and endoscopy reprocessing. Emission data were also collected for common polypectomy techniques, including cold forceps biopsy (CFB), cold snare polypectomy (CSP), hot snare polypectomy (HSP), and hot snare endoscopic mucosal resection (EMR), all performed according to standard polypectomy protocols.",[58],"Colonoscopy",[29,58,60],"Colonic polypectomy","2025-09-13",{"date":63,"type":37},"2025-09-18",{"date":39,"type":37},{"date":66,"type":21},"2025-10-31",{"name":43,"class":44},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":45},"100392795","high-dose-oral-omeprazole-in-high-risk-ugib-100392795","NCT04394663","High Dose Oral Omeprazole in High Risk UGIB","High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy; Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with peptic ulcer bleeding and endoscopic finding show ulcer with Forrest classification Ia (spurting haemorrhage), IIa (oozing haemorrhage), Ib (non-bleeding visible vessel)\n* Age \\> 18 years old\n\nExclusion Criteria:\n\n* Deny to participate\n* Pregnancy or lactation\n* Low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot\n* Non-peptic ulcer bleeding eg. erosive gastritis\u002Fduodenitis, Mallory Weiss tear, esophageal\u002Fgastric\u002Fduodenal varices, vascular lesions (eg. Dieulafoy) , malignant ulcer\n* Bleeding tendency\n* Terminal stage of cancer\n* ESRD on hemodialysis\n* Decompensated liver cirrhosis",{"count":77,"type":21},128,"INTERVENTIONAL",[80],"NA","Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent re-bleeding. Intravenous PPI is recommended as a standard treatment. In the past, there were many trials showing the efficacy of high-dose oral PPI after endoscopic hemostasis but most were industrial sponsor which assessing an expensive PPI. Moreover, the number of patients in those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by using oral PPI. This study will evaluate a high-dose, local-made PPI (omeprazole) in peptic ulcer treatment after successful endoscopic hemostasis compared to standard IV PPI continuous drip in term of rebleeding, as well as 24-hour gastric pH monitoring.",[83],"GI Bleeding",[85],"oral proton pump inhibitor","2025-09-12",{"date":63,"type":37},{"date":89,"type":37},"2020-10-01",{"date":41,"type":21},{"name":43,"class":44},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":99,"targetDuration":4,"studyType":78,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":68},"100585781","comparing-reticulocyte-hemoglobin-and-transferrin-saturation-to-guide-iron-treatment-in-people-on-dialysis-100585781","NCT06906835","Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis","Efficacy of Reticulocyte Hemoglobin Equivalent-guided Versus Transferrin Saturation-guided Iron Supplement Protocol in Hemodialysis Patients: A Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult (age 18-80 years)\n* ESKD on chronic hemodialysis ≥ 6 months\n* EPO therapy ≥ 6 months\n* Hb \\\u003C 13.0 g\u002FdL in male, \\\u003C 12.0 g\u002FdL in female\n\nExclusion Criteria:\n\n* Serum ferritin \\> 800 ng\u002FmL or TSAT \\> 40%\n* Active infection or malignancy\n* Hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease\n* History of marrow suppressive or immunosuppressive medications in past 6 months\n* History of active heart failure and recent myocardial infarction \u002Fstroke in past 6 months\n* History of GI or external bleeding or receiving blood transfusion in past 6 months",{"count":100,"type":21},160,[80],"The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia.\n\nThe main questions it aims to answer are:\n\nCan using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatment be as effective as using transferrin saturation (TSAT)?\n\nDoes the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions?\n\nResearchers will compare RET-He-guided iron treatment with TSAT-guided iron treatment to see if RET-He works just as well and has similar or better outcomes.\n\nParticipants will:\n\nReceive IV iron based on either RET-He or TSAT levels\n\nHave blood tests done at the start, 3 months, and 6 months\n\nHave their doses of iron and erythropoietin (a medication to treat anemia) adjusted based on the assigned protocol\n\nBe monitored for clinical outcomes such as hospitalization, heart events, and infections",[104,105],"Hemodialysis","Anemia in End Stage Renal Disease",[107,108,109,105,104],"Reticulocyte hemoglobin equivalent","Transferrin Saturation","Intravenous Iron Supplementation","2025-04-01",{"date":112,"type":37},"2025-04-04",{"date":114,"type":37},"2025-01-31",{"date":116,"type":21},"2025-09-30",{"name":43,"class":44},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":78,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100538334","efficacy-and-safety-of-retrograde-intraarticular-injection-topical-soaking-of-tranexamic-acid-txa-or-placebo-in-femoral-neck-fractured-patients-undergoing-cementless-bipolar-hemiarthroplasty-100538334","NCT06289478","Efficacy and Safety of Retrograde Intraarticular Injection, Topical Soaking of Tranexamic Acid (TXA), or Placebo in Femoral Neck Fractured Patients Undergoing Cementless Bipolar Hemiarthroplasty","Efficacy and Safety of Retrograde Intraarticular Injection Via Drain Tube, Topical Soaking of Tranexamic Acid (TXA), or Placebo in Elderly Patients With Femoral Neck Fractures Undergoing Bipolar Hemiarthroplasty","TXA","Inclusion Criteria:\n\n* Elderly patients (age \\> 60 years)\n* Femoral neck fractures from low energy mechanism\n* Household ambulator\n* Undergoing cementless bipolar hemiarthroplasty at KCMH\n* Informed consent\n\nExclusion Criteria:\n\n* Allergy to TXA\n* History of VTE\n* History of hip surgery, pathological fracture, hip infection\n* Congenital or acquired coagulopathy\n* Hb \\< 10 g\u002FdL or Platelet \\< 140,000",true,"60 Years",{"count":20,"type":21},[80],"The goal of this Randomized controlled trial is to evaluate in household ambulatory, elderly patients sustaining femoral neck fracture who are subjected to be treat with cementless bipolar hemiarthroplasty. The main questions it aims to answer are:\n\n* The efficacy in reducing blood transfusion for topical tranexamic acid administration\n* The safety of tranexemic acid, topically used\n\nAs having undergone bipolar hemiarthroplasty surgery, participants will either receive retrograde intraarticular tranexamic acid injection via drain tube, or topical soaking administration.\n\nResearchers will compare, with standard procedure (procedure), whether topically administered tranexamic acid would reduce rate of blood transfusion.",[132],"Femoral Neck Fracture",[134,135,136,137,138],"tranexamic acid","femoral neck fracture","bipolar hemiarthroplasty","topical","blood transfusion","2024-10-27",{"date":141,"type":37},"2024-10-30",{"date":143,"type":37},"2024-07-03",{"date":145,"type":21},"2026-04",{"name":43,"class":44},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":126,"sex":16,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":22,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":68},"100544924","investigating-neurocognitive-disorders-epidemiology-100544924","NCT06375213","Investigating Neurocognitive Disorders Epidemiology","INDE","1. Cognitively Healthy Individuals\n\n   INCLUSION CRITERIA\n   * Demonstrate normal cognitive function within the expected range on objective cognitive tests.\n   * Proficient in speaking and understanding Thai without the need for a translator to participate.\n\n   EXCLUSION CRITERIA\n   * Significant neurological or uncontrolled psychiatric illness.\n   * Significant unstable systemic condition or end-stage organ failure that affects study participation.\n2. Mild Cognitive Impairment\n\n   INCLUSION CRITERIA\n   * Display impaired\u002Fabnormal performance on objective cognitive tests.\n   * Does not meet criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5).\n   * Proficient in speaking and understanding Thai without the need for a translator to participate.\n\n   EXCLUSION CRITERIA\n   * Significant neurological or uncontrolled psychiatric illness.\n   * Significant unstable systemic condition or end-stage organ failure that affects study participation.\n3. Late Onset Dementia\n\n   INCLUSION CRITERIA\n   * Display impaired\u002Fabnormal performance on objective cognitive tests.\n   * Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.\n   * Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring after the age of 65.\n   * Proficient in speaking and understanding Thai without the need for a translator to participate.\n\n   EXCLUSION CRITERIA\n   * Significant neurological or uncontrolled psychiatric illness.\n   * Significant unstable systemic condition or end-stage organ failure that affects study participation.\n4. Early Onset Dementia\n\nINCLUSION CRITERIA\n\n* Display impaired\u002Fabnormal performance on objective cognitive tests.\n* Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.\n* Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring before the age of 65.\n* Proficient in speaking and understanding Thai without the need for a translator to participate.\n\nEXCLUSION CRITERIA\n\n* Significant neurological or uncontrolled psychiatric illness.\n* Significant unstable systemic condition or end-stage organ failure that affects study participation.","35 Years",{"count":156,"type":21},990,"8 Years","This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical\u002Fcomputational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially.",[160,161,162],"Dementia","Cognitive Decline","Alzheimer Disease","2024-04-18",{"date":165,"type":37},"2024-04-22",{"date":167,"type":37},"2023-08-24",{"date":169,"type":21},"2035-08-24",{"name":43,"class":44},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":179,"targetDuration":4,"studyType":78,"phases":181,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":68},"100291266","furosemide-stress-test-predicting-early-graft-function-in-kidney-transplantation-100291266","NCT03071536","Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation","Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function","FOSTIK","Inclusion Criteria:\n\n* Deceased donor kidney transplantation at KCMH\n* informed consent is accepted\n\nExclusion Criteria:\n\n* Known allergy to furosemide\n* Surgical complication of allograft\n* Urgently needed for dialysis (refractory hypervolemia, uremic symptoms, and hyperkalemia)",{"count":180,"type":21},180,[80],"Furosemide is an old drug that has been used frequently in the postoperative period of kidney transplantation, aiming to achieve adequate urine output. There is no previous study that directly evaluate the urine response to standardized dose of furosemide in the postoperative period. The objective is to measure the urine output after standardized dose of furosemide is delivered, as a biomarker to predict the graft function in perioperative period.",[184,185,186],"Kidney Function","Kidney Transplant; Complications","Delayed Graft Function",[188,189,190,191,192],"furosemide stress test","kidney transplantation","urine output","perioperation","delayed graft function","2024-01-15",{"date":195,"type":37},"2024-01-17",{"date":197,"type":37},"2016-11-25",{"date":199,"type":21},"2027-05",{"name":43,"class":44},""]